Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

About Rare Cancers

Rare cancers are generally classified in the group of rare diseases which is defined in the European Union as diseases with a prevalence of fewer than 5 cases out of a population of 10,000. A table published by the European Medicines Agency (EMA) with information on relevant sources for prevalence data for orphan conditions can be downloaded from the EMA Website.

Prevalence – the number of patients with the same diagnosis at a given time – is affected by mortality. However, it has been proposed by the Surveillance of Rare Cancers in Europe (RARECARE) project to consider a definition of rare cancers based on incidence, meaning the number of newly-diagnosed cases per year.*

According to this definition, rare cancers are identified as those with an incidence of less than 6 per 100,000 persons per year. Using this definition would help minimise the risk of mistaking a rare cancer (such as testicular cancer), which is frequently cured and thus has a rather high prevalence, for a common cancer, or a frequent cancer (such as small-cell lung cancer), which has a low life expectancy and thus a low prevalence, for a rare cancer.

More information on the epidemiology of rare cancers is available here: rarecarenet.istitutotumori.mi.it

See also the guidance for deliberations on rare cancer trial closures issued by the U.S. National Cancer Institute (NCI) Office of Cancer Centres on 22 May 2012.

*More information is available here: pubmed.ncbi.nlm.nih.gov

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings